Clinical Trial: Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC

U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07480694) titled 'Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC' on March 14.

Brief Summary: This study is a real-world study. we collected patients with advanced HER2-negative breast cancer previously treated with antibody-drug conjugates, and received eribulin mesylate-based therapy post-ADC. We retrospectively collect the data on previous systemic treatment, and prospectively collect the treatment data of the therapeutic regimens based on eribulin mesylate.

Study Start Date: March, 2026

Study Type: OBSERVATIONAL

Condition: Treatment Efficacy

Recruitment Status: NOT_YET_RECRU...